Agilent, 858700-913, AdvanceBio Glycan Mapping 300Å, 2.1 x 100 mm, 1.8 µm

AdvanceBio Glycan Mapping 300Å, 2.1 x 100 mm, 1.8 µm. This UHPLC column has totally porous particles with amide HILIC chemistry.

Specifications:
Brand: AdvanceBio Glycan Mapping
Hardware: SS
Inner Diameter (ID): 2.1 mm
LC Platform: Stainless Steel
Length: 100 mm
Maximum Temperature: 40 °C
Part Number Application: Glycan Analysis
Part Number Application Domain: Biopharma
Particle Size: 1.8 µm
Particle Type: Fully Porous
Phase: Amide HILIC
Pore Size: 300 Å
Pressure Rating: 1200 bar
Separation Mode: HILIC
Shipping Solvent: Acetonitrile/Water
Technique: LC & LC/MS
UNSPSC Code: 41115711
pH Range: 2-7

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
Designed for high-resolution glycan analysis, this HPLC column features a 300-angstrom pore size and 1.8-micron particle technology for rapid, sensitive separation of released N-linked and O-linked glycans. With dimensions of 2.1 x 100 mm, it allows researchers to efficiently characterize glycosylation profiles in biotherapeutic research, quality control, and biosimilar development. Its optimized particle engineering enhances peak shape and reproducibility, supporting detailed glycan mapping and structural elucidation.

Ideal for laboratories focused on monoclonal antibody development, vaccine design, or glycoprotein analysis, this column delivers reliable and robust performance even with complex sample matrices. It integrates seamlessly with Agilent InfinityLab LC Series instruments and is fully compatible with most UHPLC and HPLC systems, ensuring broad applicability. This product also complements related AdvanceBio sample preparation kits, reference standards, and a suite of glycan analysis software tools, enabling a comprehensive workflow from sample preparation to data interpretation. By ensuring consistent, high-efficiency separation, it supports regulatory compliance and enhances confidence in critical quality attribute assessment for biopharmaceutical products.